Insurance companies lose Medicare reimbursement role
This article was originally published in Clinica
The Health Care Financing Administration has removed insurance company executives from Medicare's Technology Advisory Committee after concerns were raised about the panel's practice of meeting in private.
You may also be interested in...
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.